As of 2025-07-03, the EV/EBITDA ratio of Prometheus Biosciences Inc (RXDX) is -58.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Prometheus's latest enterprise value is 9,445.47 mil USD. Prometheus's TTM EBITDA according to its financial statements is -161.61 mil USD. Dividing these 2 quantities gives us the above Prometheus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 12.5x | 10.4x |
| Forward P/E multiples | 11.6x - 20.2x | 15.9x |
| Fair Price | (36.84) - (39.88) | (41.99) |
| Upside | -118.4% - -119.9% | -121.0% |
| Date | EV/EBITDA |